Results 31 to 40 of about 4,504 (155)
, 2014 The high morbidity and mortality associated with invasive fungal infections have increased the importance of improving treatment efficacy. Posaconazole is a novel agent with strong antifungal activity and low toxicity.
Liao, Hsiao-Wei;Lin, Shu-Wen;Wu, Un-In;Kuo, Ching-Hua +1 more
core +1 more source
Medical Mycology Case Reports, 2021 Mucorales infections in cetaceans have a high mortality rate. This case report refers to a bottlenose dolphin calf with suspected mucormycosis treated with posaconazole.
Gonçalo N. Marques +3 more
doaj +1 more source
Therapeutic Drug Monitoring of Posaconazole: an Update [PDF]
, 2016 Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced ...
Anette Veringa +15 more
core +3 more sources
The tablet formulation of posaconazole: clinical pharmacology and the use in patients with hematologic malignancies [PDF]
Клиническая микробиология и антимикробная химиотерапия, 2020 Posaconazole is a broad-spectrum triazole antifungal agent with potent activity against various fungi, including yeast and molds, including Mucorales, what makes a key difference with itraconazole and voriconazole.
Veselov A.V.
doaj +1 more source
Drugs in R & D, 2003 Posaconazole [SCH 56592, SPRIAFIL, Noxafil] is an orally active triazole derivative that is in phase III trials with the Schering-Plough Research Institute (SPRI) in the US for the treatment of serious opportunistic fungal infections, including aspergillosis, candidiasis, coccidioidomycosis and fusariosis.
openaire +2 more sources
Clinical and Translational SciencePosaconazole is a broad‐spectrum triazole antifungal agent indicated for the prophylaxis and treatment of invasive fungal infections. Posaconazole pharmacokinetics and drug–drug interactions (DDIs), due to cytochrome P450 3A4 (CYP3A4) inhibition, have ...
Rebecca E. Wrishko +3 more
doaj +1 more source
Phytotherapy Research, EarlyView.ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit +5 more
wiley +1 more source
Posaconazole-Induced Adrenal Insufficiency in a Case of Chronic Myelomonocytic Leukemia
Case Reports in Endocrinology, 2018 Introduction. Posaconazole is an azole used in treatment and prophylaxis of a broad spectrum of fungal infections. Antifungals such as ketoconazole have been shown to cause primary adrenal insufficiency (AI) as a result of direct inhibition on the ...
Ann Miller +3 more
doaj +1 more source
Australian Veterinary Journal, EarlyView.A 3‐year‐old male Border Collie diagnosed with immune‐mediated dermatopathy, managed with tapering prednisolone and cyclosporine, developed rapidly progressive ocular signs and additional cutaneous lesions. Histopathology, mycological culture, polymerase chain reaction and sequencing confirmed intraocular and cutaneous infection due to Curvularia ...
T Brasil‐Ervedosa +4 more
wiley +1 more source
, 2013 Stereoscopic view of posaconazole docked in the active site CYP51Tc in pose 1 (yellow) and pose 2 (pink). Residues within 4 Å of posaconazole (green) are shown.
Matthew P. Jacobson (174588) +5 more
core +1 more source